SAN DIEGO, Dec. 3 Biocept, Inc. ("Biocept"), an emergingleader in biotechnology, announced today their CLIA laboratory has beenawarded accreditation by the Commission on Laboratory Accreditation of theCollege of American Pathologists (CAP), based on the results of a recenton-site inspection. The laboratory's director, Philip D. Cotter, Ph.D., FACMG,was advised of this national recognition and congratulated for the "excellenceof services being provided."
Biocept, an emerging biotechnology leader in cell separation technology,is developing a new, powerful class of diagnostic assays for personalizedmedicine in early detection, diagnosis and monitoring of cancer. The CEE(TM)Cell Enrichment and Extraction platform combines sophisticated attachmentchemistry with mathematically modeled fluid dynamics and nanotechnology toenable earlier, accurate, less invasive diagnoses. Isolation, purification andanalysis of rare cells, such as circulating tumor cells, are managed withinour state-of-the-art CLIA-accredited laboratory. The clinical laboratory isaccredited by the College of American Pathologists (CAP) and holds licenses inCalifornia and several other states.
SOURCE Biocept, Inc.